Abstract 11584: Direct Oral Anti-coagulation Significantly Reduces Mortality in Atrial Fibrillation Academic Article uri icon

abstract

  • Introduction: Direct anticoagulants (DOACs) have demonstrated significant reduction in stroke and all-cause mortality rates in non-valvular atrial fibrillation (NVAF) patients. However, utilization of DOACs is still limited, with many patients not receiving any anticoagulation therapy. Data on long-term mortality implications of DOAC underutilization in the general NVAF population is limited. Our objective was to explore the effect of DOACs on mortality of NVAF patients in a clinical practice setting with long-term follow-up.Hypothesis: We assessed the hypothesis that DOAC therapy significantly reduces mortality in eligible NVAF patients.Methods: We identified all NVAF patients eligible by Israel guidelines for DOAC therapy (CHADS2 ≥2) in Clalit Health Services from 2011 to 2016. Mean age of eligibility to DOAC therapy was 78 in both groups. Patients were followed to May 15, 2017, or death event. Drug adherence was assessed based on electronic records of DOAC prescription data. Patients were consider

publication date

  • November 14, 2017